<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Antimicrob Agents</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Antimicrob. Agents</journal-id><journal-title-group><journal-title>International Journal of Antimicrobial Agents</journal-title></journal-title-group><issn pub-type="ppub">0924-8579</issn><issn pub-type="epub">1872-7913</issn><publisher><publisher-name>Elsevier Ltd and International Society of Antimicrobial Chemotherapy.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7391054</article-id><article-id pub-id-type="publisher-id">S0924-8579(20)30308-3</article-id><article-id pub-id-type="doi">10.1016/j.ijantimicag.2020.106125</article-id><article-id pub-id-type="publisher-id">106125</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms?</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name><surname>Alonso</surname><given-names>Daniel F.</given-names></name><email>dfalonso@unq.edu.ar</email><xref rid="cor0001" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="au0002"><name><surname>Farina</surname><given-names>Hern&#x000e1;n G.</given-names></name></contrib><aff id="aff0001">Laboratory of Molecular Oncology, Department of Science and Technology, National University of Quilmes, Buenos Aires, Argentina</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#x0204e;</label>Corresponding author. Present address: R. S&#x000e1;enz Pe&#x000f1;a 325, B1876BXD Bernal, Provincia de Buenos Aires, Argentina <email>dfalonso@unq.edu.ar</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>30</day><month>7</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>9</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>30</day><month>7</month><year>2020</year></pub-date><volume>56</volume><issue>3</issue><fpage>106125</fpage><lpage>106125</lpage><history><date date-type="received"><day>27</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>23</day><month>7</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier Ltd</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions></article-meta></front><body><p content-type="salutation">Sir,</p><p id="para0002">Drug repurposing, also called repositioning or rediscovering, refers to the process of developing a known drug for a novel use that is different from its original clinical indication. This concept has focused great attention on the search for viable treatments in the context of the current coronavirus disease 2019 (COVID-19) pandemic. The recently published article by Serafin et&#x000a0;al. in the <italic>International Journal of Antimicrobial Agents</italic>
<xref rid="bib0001" ref-type="bibr">[1]</xref> presented a selection of repurposing drug candidates for potential use in the management of COVID-19. The authors conducted a systematic search of PubMed, Scopus and Web of Science databases and identified recent studies investigating drugs from different pharmaceutical classes with antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV. Remarkably, at least four drugs reported by Serafin et&#x000a0;al. with promising early results in COVID-19 <xref rid="bib0001" ref-type="bibr">[1]</xref>, including hydroxychloroquine, chloroquine, nitazoxanide and metformin, have also been previously explored as anticancer agents. The antimalarials hydroxychloroquine and chloroquine are known to inhibit autophagic pathways in aggressive metastatic cells and potentiate the efficacy of chemotherapy in various types of cancer. Autophagy is considered a cytoprotective mechanism that confers drug resistance, representing a key obstacle to effective cancer treatment <xref rid="bib0002" ref-type="bibr">[2]</xref>. Likewise, the antiparasitic drug nitazoxanide induces cancer cell cytotoxicity under hypoxic conditions and could be an excellent candidate to target dormant cancer cells in hypoxic regions of tumours in combination with chemotherapeutic agents <xref rid="bib0003" ref-type="bibr">[3]</xref>. Metformin, an effective medication used in type 2 diabetes mellitus, is able to modulate tumour cell signalling and metabolism. Although the underlying mechanisms have not been completely characterised, metformin reduces tumour cell growth, inhibits the expression of microRNAs associated with tumorigenesis, and limits energy availability by affecting mitochondrial metabolism <xref rid="bib0004" ref-type="bibr">[4]</xref>. Moreover, cell starvation caused by metformin triggers the release of cytokines such as interleukins IL-6 and IL-8, and promotes recruitment of immune cells in the tumour microenvironment <xref rid="bib0005" ref-type="bibr">[5]</xref>.</p><p id="para0003">We would like to add some comments regarding the importance of drug repurposing as an emerging approach for the development of host-based antiviral agents, highlighting similarities between antiviral and antitumour mechanisms, when considering other drugs such as lovastatin and ivermectin. Development of host-based antiviral strategies is emerging as an attractive approach to complement the treatment of patients with severe COVID-19 at risk for acute respiratory disease syndrome (ARDS). Clinically approved drugs could be used to target viral entry or viral replication as well as to modulate the innate immune responses <xref rid="bib0006" ref-type="bibr">[6]</xref>. Mechanisms essential for viral infection, such as host cell proteolytic processing, endocytosis, nuclear transport and intracellular signal transduction, among others, have been indicated as better targets to identify broad-spectrum antiviral agents, with some advantages over direct-acting antivirals targeting viral components. For instance, host-based therapeutics could overcome limitations associated with drug resistance or viral mutations.</p><p id="para0004">Well-tolerated compounds with documented antitumour properties are attractive as potential host-based drug candidates for the management of critically ill COVID-19 patients. Lovastatin, a fungal antibiotic used in the treatment of hypercholesterolaemia since the mid-1980s, has been demonstrated to produce potent antitumour effects in experimental mouse models at non-cytotoxic concentrations <xref rid="bib0007" ref-type="bibr">[7]</xref>. In particular, lovastatin holds promise for the clinical management of triple-negative breast cancer <xref rid="bib0008" ref-type="bibr">[8]</xref>. The compound reduces membrane localisation of Rho proteins, thus affecting signalling molecules involved in regulation of the actin cytoskeleton during tumour cell migration and metastatic colonisation <xref rid="bib0009" ref-type="bibr">[9]</xref>. Interestingly, it is known that RhoA signalling is also associated with cellular functions that are relevant to the pathogenesis of several viral infections, including actin organisation and the production of proinflammatory cytokines <xref rid="bib0010" ref-type="bibr">[10]</xref>. It appears that cholesterol depletion by lovastatin causes the shutdown of host cell signals required for viral pathogenesis, similar to the effects on tumour cell signalling.</p><p id="para0005">Lovastatin and other lipophilic statins such as simvastatin and atorvastatin also have profound effects on endothelial cell biology, and it is known that the angiostatic action plays a key role in statin-induced antitumour activity <xref rid="bib0011" ref-type="bibr">[11]</xref>. Likewise, by targeting the host response to infection, statins act on endothelial dysfunction and may contribute to the return to homeostasis in patients with severe COVID-19 <xref rid="bib0012" ref-type="bibr">[12]</xref>. Statins, as well as angiotensin receptor blockers, are able to upregulate angiotensin-converting enzyme 2 (ACE2) [<xref rid="bib0013" ref-type="bibr">13</xref>,<xref rid="bib0014" ref-type="bibr">14</xref>], which is the viral entry receptor for SARS-CoV-2 <xref rid="bib0015" ref-type="bibr">[15]</xref>. However, there is presently no evidence indicating that these medications enhance viral entry into host cells. In fact, once COVID-19 infection has progressed, ACE2 mediates protective effects against lung injury <xref rid="bib0016" ref-type="bibr">[16]</xref>, and elevated levels of ACE2 are associated with a reduced severity of ARDS <xref rid="bib0017" ref-type="bibr">[17]</xref>. Hence, treatment strategies that modulate the host response by manipulating the renin&#x02013;angiotensin system might attenuate the destructive lung disease associated with COVID-19 [<xref rid="bib0012" ref-type="bibr">12</xref>,<xref rid="bib0016" ref-type="bibr">16</xref>].</p><p id="para0006">The well-known antiparasitic drug ivermectin has been reported to possess antiviral activity against a wide range of viruses as well as to display promising antitumour effects in different preclinical models of aggressive cancers <xref rid="bib0018" ref-type="bibr">[18]</xref>. Ivermectin appears to produce pleiotropic actions in virus-infected host cells and malignant tumour cells, but the precise mechanisms are not completely understood. Among other actions, ivermectin affects tumour cell growth, induces caspase-dependent apoptosis, and causes immunogenic cell death <xref rid="bib0019" ref-type="bibr">[19]</xref>. A few years ago, ivermectin was reported to affect the interaction between the integrase protein of human immunodeficiency virus 1 (HIV-1) and the importin heterodimer &#x003b1;/&#x003b2;1. The drug was later confirmed to behave as a potent inhibitor of the nuclear import mechanisms of viral proteins in host cells, including SV40 simian virus large tumour antigen and dengue virus non-structural proteins <xref rid="bib0020" ref-type="bibr">[20]</xref>. Very recently, it was proposed as a mechanism for inhibiting the entry and replication of SARS-CoV-2 <xref rid="bib0021" ref-type="bibr">[21]</xref>. Interestingly, this mechanism of inhibition of nuclear protein trafficking had been suggested as a potential universal target against RNA viruses <xref rid="bib0022" ref-type="bibr">[22]</xref> and could also explain part of the antitumour properties of ivermectin <xref rid="bib0023" ref-type="bibr">[23]</xref>. In this regard, nuclear transport plays a central role in cancer by moving key mediators of carcinogenesis across the nuclear pore <xref rid="bib0024" ref-type="bibr">[24]</xref>.</p><p id="para0007">Altogether these evidences stress the importance of host-based strategies in the rapid identification of therapies for COVID-19 patients and, in particular, underscore the potential of certain repurposed drugs with known antitumour activity. Drug repurposing permits reduced development time and cost and implies lesser safety concerns as data on long-term pharmacovigilance for adverse effects are already available. <xref rid="tbl0001" ref-type="table">Table&#x000a0;1</xref>
presents a summary of selected repurposed drugs, their original medical indications, and potential mechanisms of action. Drugs such as lovastatin, ivermectin, metformin and nitazoxanide constitute promising therapeutic approaches that deserve clinical testing in COVID-19, either alone or as components of antiviral therapy regimens.<table-wrap position="float" id="tbl0001"><label>Table 1</label><caption><p>Selected repurposed drugs with antitumour effects and potential antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</p></caption><alt-text id="alt0001">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top">Drug</th><th valign="top">Original indication</th><th valign="top">Potential antitumour/antiviral mechanisms of action</th><th valign="top">References</th></tr></thead><tbody><tr><td valign="top">Lovastatin <xref rid="tb1fn1" ref-type="table-fn">a</xref></td><td valign="top">Cholesterol-lowering drug</td><td valign="top">Inhibits Rho signalling associated with tumour spread and viral pathogenesis.</td><td valign="top">[<xref rid="bib0009" ref-type="bibr">9</xref>,<xref rid="bib0012" ref-type="bibr">12</xref>]</td></tr><tr><td valign="top"/><td valign="top"/><td valign="top">Counteracts tumour angiogenesis and endothelial dysfunction in ARDS</td><td valign="top"/></tr><tr><td valign="top">Ivermectin</td><td valign="top">Antiparasitic agent</td><td valign="top">Inhibits nuclear import mechanisms of oncoproteins and viral proteins.</td><td valign="top">[<xref rid="bib0019" ref-type="bibr">19</xref>,<xref rid="bib0021" ref-type="bibr">21</xref>]</td></tr><tr><td valign="top"/><td valign="top"/><td valign="top">Induces immunogenic cell death</td><td valign="top"/></tr><tr><td valign="top">Metformin</td><td valign="top">Hypoglycaemic drug</td><td valign="top">Among various effects, triggers cytokine release and recruits immune cells</td><td valign="top">[<xref rid="bib0001" ref-type="bibr">1</xref>,<xref rid="bib0005" ref-type="bibr">5</xref>]</td></tr><tr><td valign="top">Nitazoxanide</td><td valign="top">Antiparasitic agent</td><td valign="top">Not clearly defined. Induces cell cytotoxicity under hypoxic conditions</td><td valign="top">[<xref rid="bib0001" ref-type="bibr">1</xref>,<xref rid="bib0003" ref-type="bibr">3</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>ARDS, acute respiratory disease syndrome.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb1fn1"><label>a</label><p id="notep0002">Other lipophilic statins such as simvastatin and atorvastatin share similar antitumour and/or antiviral effects.</p></fn></table-wrap-foot></table-wrap></p></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name><surname>Serafin</surname><given-names>MB</given-names></name><name><surname>Bottega</surname><given-names>A</given-names></name><name><surname>Foletto</surname><given-names>VS</given-names></name><name><surname>da Rosa</surname><given-names>TF</given-names></name><name><surname>H&#x000f6;rner</surname><given-names>A</given-names></name><name><surname>H&#x000f6;rner</surname><given-names>R</given-names></name></person-group><article-title>Drug repositioning is an alternative for the treatment of coronavirus COVID-19</article-title><source>Int J Antimicrob Agents</source><volume>55</volume><year>2020</year><object-id pub-id-type="publisher-id">105969</object-id><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105969</pub-id></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>Combination of an autophagy inducer and an autophagy inhibitor: a smarter strategy emerging in cancer therapy</article-title><source>Front Pharmacol</source><volume>11</volume><year>2020</year><fpage>408</fpage><pub-id pub-id-type="doi">10.3389/fphar.2020.00408</pub-id><pub-id pub-id-type="pmid">32322202</pub-id></element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name><surname>Senkowski</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Olofsson</surname><given-names>MH</given-names></name><name><surname>Isacson</surname><given-names>R</given-names></name><name><surname>H&#x000f6;glund</surname><given-names>U</given-names></name><name><surname>Gustafsson</surname><given-names>M</given-names></name></person-group><article-title>Three-dimensional cell culture-based screening identifies the anthelmintic drug nitazoxanide as a candidate for treatment of colorectal cancer</article-title><source>Mol Cancer Ther</source><volume>14</volume><year>2015</year><fpage>1504</fpage><lpage>1516</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-14-0792</pub-id><pub-id pub-id-type="pmid">25911689</pub-id></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Lv</surname><given-names>H</given-names></name><name><surname>Shang</surname><given-names>P</given-names></name></person-group><article-title>Anticancer mechanisms of metformin: a review of the current evidence</article-title><source>Life Sci</source><volume>24</volume><year>2020</year><object-id pub-id-type="publisher-id">117717</object-id><pub-id pub-id-type="doi">10.1016/j.lfs.2020.117717</pub-id></element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>P&#x000fc;schel</surname><given-names>F</given-names></name><name><surname>Favaro</surname><given-names>F</given-names></name><name><surname>Redondo-Pedraza</surname><given-names>J</given-names></name><name><surname>Lucendo</surname><given-names>E</given-names></name><name><surname>Iurlaro</surname><given-names>R</given-names></name><name><surname>Marchetti</surname><given-names>S</given-names></name></person-group><article-title>Starvation and antimetabolic therapy promote cytokine release and recruitment of immune cells</article-title><source>Proc Natl Acad Sci U S A</source><volume>117</volume><year>2020</year><fpage>9932</fpage><lpage>9941</lpage><pub-id pub-id-type="doi">10.1073/pnas.1913707117</pub-id><pub-id pub-id-type="pmid">32312819</pub-id></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name><surname>Li</surname><given-names>CC</given-names></name><name><surname>Wang</surname><given-names>XJ</given-names></name><name><surname>Wang</surname><given-names>HR</given-names></name></person-group><article-title>Repurposing host-based therapeutics to control coronavirus and influenza virus</article-title><source>Drug Discov Today</source><volume>24</volume><year>2019</year><fpage>726</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2019.01.018</pub-id><pub-id pub-id-type="pmid">30711575</pub-id></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name><surname>Alonso</surname><given-names>DF</given-names></name><name><surname>Farina</surname><given-names>HG</given-names></name><name><surname>Skilton</surname><given-names>G</given-names></name><name><surname>Gabri</surname><given-names>MR</given-names></name><name><surname>De Lorenzo</surname><given-names>MS</given-names></name><name><surname>Gomez</surname><given-names>DE</given-names></name></person-group><article-title>Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis</article-title><source>Breast Cancer Res Treat</source><volume>50</volume><year>1998</year><fpage>83</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1023/a:1006058409974</pub-id><pub-id pub-id-type="pmid">9802623</pub-id></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>G</given-names></name><name><surname>Yan</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Rosol</surname><given-names>TJ</given-names></name></person-group><article-title>Triple-negative breast cancer: is there a treatment on the horizon?</article-title><source>Oncotarget</source><volume>8</volume><year>2017</year><fpage>1913</fpage><lpage>1924</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.12284</pub-id><pub-id pub-id-type="pmid">27765921</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name><surname>Farina</surname><given-names>HG</given-names></name><name><surname>Bublik</surname><given-names>DR</given-names></name><name><surname>Alonso</surname><given-names>DF</given-names></name><name><surname>Gomez</surname><given-names>DE</given-names></name></person-group><article-title>Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells</article-title><source>Clin Exp Metastasis</source><volume>19</volume><year>2002</year><fpage>551</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1023/a:1020355621043</pub-id><pub-id pub-id-type="pmid">12405293</pub-id></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>Gower</surname><given-names>TL</given-names></name><name><surname>Peeples</surname><given-names>ME</given-names></name><name><surname>Collins</surname><given-names>PL</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name></person-group><article-title>RhoA is activated during respiratory syncytial virus infection</article-title><source>Virology</source><volume>283</volume><year>2001</year><fpage>188</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1006/viro.2001.0891</pub-id><pub-id pub-id-type="pmid">11336544</pub-id></element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name><surname>Sopkov&#x000e1;</surname><given-names>J</given-names></name><name><surname>Vidomanov&#x000e1;</surname><given-names>E</given-names></name><name><surname>Strn&#x000e1;del</surname><given-names>J</given-names></name><name><surname>&#x00160;kovierov&#x000e1;</surname><given-names>H</given-names></name><name><surname>Hala&#x00161;ov&#x000e1;</surname><given-names>E</given-names></name></person-group><article-title>The role of statins as therapeutic agents in cancer</article-title><source>Gen Physiol Biophys</source><volume>36</volume><year>2017</year><fpage>501</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.4149/gpb_2017045</pub-id><pub-id pub-id-type="pmid">29372683</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name><surname>Fedson</surname><given-names>DS</given-names></name><name><surname>Opal</surname><given-names>SM</given-names></name><name><surname>Rordam</surname><given-names>OM</given-names></name></person-group><article-title>Hiding in plain sight: an approach to treating patients with severe COVID-19 infection</article-title><source>mBio</source><volume>11</volume><year>2020</year><pub-id pub-id-type="doi">10.1128/mBio.00398-20</pub-id><comment>e00398-20</comment></element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name><surname>Tikoo</surname><given-names>K</given-names></name><name><surname>Patel</surname><given-names>G</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Karpe</surname><given-names>PA</given-names></name><name><surname>Sanghavi</surname><given-names>M</given-names></name><name><surname>Malek</surname><given-names>V</given-names></name></person-group><article-title>Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications</article-title><source>Biochem Pharmacol</source><volume>93</volume><year>2015</year><fpage>343</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2014.11.013</pub-id><pub-id pub-id-type="pmid">25482567</pub-id></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name><surname>Ferrario</surname><given-names>CM</given-names></name><name><surname>Jessup</surname><given-names>J</given-names></name><name><surname>Chappell</surname><given-names>MC</given-names></name><name><surname>Averill</surname><given-names>DB</given-names></name><name><surname>Brosnihan</surname><given-names>KB</given-names></name><name><surname>Tallant</surname><given-names>EA</given-names></name></person-group><article-title>Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2</article-title><source>Circulation</source><volume>111</volume><year>2005</year><fpage>2605</fpage><lpage>2610</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.104.510461</pub-id><pub-id pub-id-type="pmid">15897343</pub-id></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>J</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>C</given-names></name><name><surname>Ye</surname><given-names>G</given-names></name><name><surname>Geng</surname><given-names>Q</given-names></name><name><surname>Auerbach</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>F</given-names></name></person-group><article-title>Cell entry mechanisms of SARS-CoV-2</article-title><source>Proc Natl Acad Sci U S A</source><volume>117</volume><year>2020</year><fpage>11727</fpage><lpage>11734</lpage><pub-id pub-id-type="doi">10.1073/pnas.2003138117</pub-id><pub-id pub-id-type="pmid">32376634</pub-id></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name><surname>Sturrock</surname><given-names>BR</given-names></name><name><surname>Milne</surname><given-names>K</given-names></name><name><surname>Chevassut</surname><given-names>TJ</given-names></name></person-group><article-title>The renin&#x02013;angiotensin system&#x02014;a therapeutic target in COVID-19?</article-title><source>Clin Med (Lond)</source><volume>20</volume><year>2020</year><fpage>e72</fpage><lpage>e75</lpage><pub-id pub-id-type="doi">10.7861/clinmed.2020-0146</pub-id><pub-id pub-id-type="pmid">32414711</pub-id></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name><surname>W&#x000f6;sten-van Asperen</surname><given-names>RM</given-names></name><name><surname>Bos</surname><given-names>AP</given-names></name><name><surname>Bem</surname><given-names>RA</given-names></name><name><surname>Dierdorp</surname><given-names>BS</given-names></name><name><surname>Dekker</surname><given-names>T</given-names></name><name><surname>van Goor</surname><given-names>H</given-names></name></person-group><article-title>Imbalance between pulmonary angiotensin-converting enzyme and angiotensin-converting enzyme 2 activity in acute respiratory distress syndrome</article-title><source>Pediatr Crit Care Med</source><volume>14</volume><year>2013</year><fpage>e438</fpage><lpage>e441</lpage><pub-id pub-id-type="doi">10.1097/PCC.0b013e3182a55735</pub-id><pub-id pub-id-type="pmid">24226567</pub-id></element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name></person-group><article-title>Progress in understanding the molecular mechanisms underlying the antitumour effects of ivermectin</article-title><source>Drug Des Devel Ther</source><volume>14</volume><year>2020</year><fpage>285</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S237393</pub-id></element-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name><surname>Draganov</surname><given-names>D</given-names></name><name><surname>Gopalakrishna-Pillai</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>YR</given-names></name><name><surname>Zuckerman</surname><given-names>N</given-names></name><name><surname>Moeller</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name></person-group><article-title>Modulation of P2X4/P2X7/pannexin-1 sensitivity to extracellular ATP via ivermectin induces a non-apoptotic and inflammatory form of cancer cell death</article-title><source>Sci Rep</source><volume>5</volume><year>2015</year><fpage>16222</fpage><pub-id pub-id-type="doi">10.1038/srep16222</pub-id><pub-id pub-id-type="pmid">26552848</pub-id></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>Wagstaff</surname><given-names>KM</given-names></name><name><surname>Sivakumaran</surname><given-names>H</given-names></name><name><surname>Heaton</surname><given-names>SM</given-names></name><name><surname>Harrich</surname><given-names>D</given-names></name><name><surname>Jans</surname><given-names>DA</given-names></name></person-group><article-title>Ivermectin is a specific inhibitor of importin &#x003b1;/&#x003b2;-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus</article-title><source>Biochem J</source><volume>443</volume><year>2012</year><fpage>851</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1042/BJ20120150</pub-id><pub-id pub-id-type="pmid">22417684</pub-id></element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name><surname>Caly</surname><given-names>L</given-names></name><name><surname>Druce</surname><given-names>JD</given-names></name><name><surname>Catton</surname><given-names>MG</given-names></name><name><surname>Jans</surname><given-names>DA</given-names></name><name><surname>Wagstaff</surname><given-names>KM</given-names></name></person-group><article-title>The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro</article-title><source>Antiviral Res</source><volume>178</volume><year>2020</year><object-id pub-id-type="publisher-id">104787</object-id><pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104787</pub-id></element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name><surname>Caly</surname><given-names>L</given-names></name><name><surname>Wagstaff</surname><given-names>KM</given-names></name><name><surname>Jans</surname><given-names>DA</given-names></name></person-group><article-title>Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?</article-title><source>Antiviral Res</source><volume>95</volume><year>2012</year><fpage>202</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2012.06.008</pub-id><pub-id pub-id-type="pmid">22750233</pub-id></element-citation></ref><ref id="bib0023"><label>23</label><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name><surname>Kosyna</surname><given-names>FK</given-names></name><name><surname>Nagel</surname><given-names>M</given-names></name><name><surname>Kluxen</surname><given-names>L</given-names></name><name><surname>Kraushaar</surname><given-names>K</given-names></name><name><surname>Depping</surname><given-names>R</given-names></name></person-group><article-title>The importin &#x003b1;/&#x003b2;-specific inhibitor ivermectin affects HIF-dependent hypoxia response pathways</article-title><source>Biol Chem</source><volume>396</volume><year>2015</year><fpage>1357</fpage><lpage>1367</lpage><pub-id pub-id-type="doi">10.1515/hsz-2015-0171</pub-id><pub-id pub-id-type="pmid">26351913</pub-id></element-citation></ref><ref id="bib0024"><label>24</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name><surname>Kosyna</surname><given-names>FK</given-names></name><name><surname>Depping</surname><given-names>R.</given-names></name></person-group><article-title>Controlling the gatekeeper: therapeutic targeting of nuclear transport</article-title><source>Cells</source><volume>7</volume><year>2018</year><fpage>221</fpage><pub-id pub-id-type="doi">10.3390/cells7110221</pub-id></element-citation></ref></ref-list><ack id="ack0001"><title>Acknowledgment</title><p>The authors thank Ms Rocio Arrua for her assistance with English language editing.</p><p>
<bold>Funding:</bold> This work was supported by the National University of Quilmes and ANPCyT (Buenos Aires, Argentina).</p><p>
<bold>Competing interests:</bold> DFA and HGF have served in a consultant/advisory role for Elea-Phoenix Laboratories and Chemo-Romikin (Argentina).</p><p>
<bold>Ethical approval:</bold> Not required.</p></ack></back></article>